WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
Charles plans to attend Royal Ascot as he tells aides: 'I want to honour the late Queen's memory'15 people suffer minor injuries in tram accident at Universal Studios theme park in Los AngelesJeremy Clarkson leads emotional tributes as BBC Top Gear legend dies aged 80The most incredible diets in sport: Erling Haaland 6,000Orlando City ties Montreal 2Rosie HuntingtonCoachella 2024: Photo highlights as weekend 2 gets underwaySuper Rugby: playoffs picture clears but system raises questionsRyan Garcia knocks Devin Haney down 3 times and hands his amateur rival his first pro lossKonnor McClain, Haleigh Bryant help LSU women win first NCAA gymnastics title
3.407s , 6503.28125 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,Culture Craft news portal